Ohio’s decision to end GLP-1 coverage for state employees is unjustified and harmful, writes Dr. Leslie Pristas, president of ...

Hims & Hers Health continues to post robust growth. Shares sold off, however, after revenue missed analyst expectations. The stock is still reasonably valued given its growth prospects. 10 stocks we ...

Scientists have uncovered a way to promote weight loss and improve blood sugar control without the unpleasant side effects of ...

Researchers at the Salk Institute have used CRISPR to uncover hidden microproteins that control fat cell growth and lipid ...

Jim Cramer isn’t sugarcoating that 2025 has been a tricky ride for investors in the S&P 500. A few AI-powered giants have been doing the bulk of the heavy lifting, while plenty of stocks are still ...

In a letter sent to Harvard President Alan M. Garber on Friday, Commerce Secretary Howard Lutnick alleges the university ...

These new supplemental products are offering similar benefits to drugs like Ozempic — but experts say it may be a placebo effect.

Eli Lilly says their obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for ...

GLP-1 Plus by Advanced BioNutritionals enters the spotlight with a patented dihydroberberine (DHB) formula in 2025, reflecting rising interest in GLP-1 alternatives and non-injection hunger support ...

Ali Eastburn was looking forward to her son's wedding when her side-effects from weight loss drugs went from bad to worse ...